EP-1351 Long-term survival with FDG-PET directed therapy in NSCLC with synchronous solitary brain metastasis

SABR-COMET: a new paradigm of care lights up the twilight of metastatic disease

“…The next arm of the STAMPEDE trial, designed to investigate the role of metastasis directed therapy after standard of care, aims to answer this question (14). Our own local series of 49 patients with non-small cell lung cancer and synchronous solitary brain metastasis who were treated radically to both sites had a five year OS of 30%, which suggests that aggressive local therapy of all sites of disease can be associated with long-term survival and possible cure (15).…”